DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Desferal (Deferoxamine Mesylate) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.

At the Injection Site:  Localized irritation, pain, burning, swelling, induration, infiltration, pruritus, erythema, wheal formation, eschar, crust, vesicles, local edema. Injection site reactions may be associated with systemic allergic reactions (see Body as a Whole, below).

Hypersensitivity Reactions and Systemic Allergic Reactions:  Generalized rash, urticaria, anaphylactic reaction with or without shock, angioedema. 

Body as a Whole: Local injection site reactions may be accompanied by systemic reactions like arthralgia, fever, headache, myalgia, nausea, vomiting, abdominal pain, or asthma.

Infections with Yersinia and Mucormycosis have been reported in association with Desferal use (see PRECAUTIONS).

Cardiovascular:  Tachycardia, hypotension, shock.

Digestive:  Abdominal discomfort, diarrhea, nausea, vomiting.

Hematologic: Blood dyscrasia (thrombocytopenia, leucopenia).

Hepatic: Increased transaminases, hepatic dysfunction.

Musculoskeletal:  Muscle spasms. Growth retardation and bone changes (e.g., metaphyseal dysplasia) are common in chelated patients given doses above 60 mg/kg, especially those who begin iron chelation in the first three years of life. If doses are kept to 40 mg/kg or below, the risk may be reduced (see WARNINGS, PRECAUTIONS/Pediatric Use).

Nervous S ystem:  Neurological disturbances including dizziness, peripheral sensory, motor, or mixed neuropathy, paresthesias, seizures; exacerbation or precipitation of aluminum-related dialysis encephalopathy (see PRECAUTIONS/Information for Patients).

Special Senses: High-frequency sensorineural hearing loss and/or tinnitus are uncommon if dosage guidelines are not exceeded and if dose is reduced when ferritin levels decline. Visual disturbances are rare if dosage guidelines are not exceeded. These may include decreased acuity, blurred vision, loss of vision, dyschromatopsia, night blindness, visual field defects, scotoma, retinopathy (pigmentary degeneration), optic neuritis, and cataracts (see WARNINGS).

Respiratory: Acute respiratory distress syndrome (with dyspnea, cyanosis, and/or interstitial infiltrates) (see WARNINGS).

Skin: Very rare generalized rash.

Urogenital:  Dysuria, acute renal failure, increased serum creatinine and renal tubular disorders (see CONTRAINDICATIONS and WARNINGS).

Postmarketing Reports

There are postmarketing reports of deferoxamine-associated renal dysfunction, including renal failure. Monitor patients for changes in renal function (e.g., increased serum creatinine).



REPORTS OF SUSPECTED DESFERAL SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Desferal. The information is not vetted and should not be considered as verified clinical evidence.

Possible Desferal side effects / adverse reactions in 13 year old male

Reported by a health professional (non-physician/pharmacist) from Germany on 2011-10-03

Patient: 13 year old male weighing 46.6 kg (102.5 pounds)

Reactions: Blood Alkaline Phosphatase Increased, Vomiting, Blood Creatine Phosphokinase Increased, Encephalopathy, Muscle Rigidity, Delirium

Adverse event resulted in: hospitalization

Suspect drug(s):
Desferal

Other drugs received by patient: Exjade



Possible Desferal side effects / adverse reactions in 79 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-12-21

Patient: 79 year old male

Reactions: Neoplasm Malignant

Adverse event resulted in: death

Suspect drug(s):
Desferal

Exjade
    Dosage: 1000 mg, qd, oral
    Administration route: Oral
    Indication: Haematopoietic Neoplasm
    Start date: 2009-02-03
    End date: 2010-11-15

Exjade
    Dosage: 1000 mg, qd, oral
    Administration route: Oral
    Indication: Lymphatic System Neoplasm
    Start date: 2009-02-03
    End date: 2010-11-15



Possible Desferal side effects / adverse reactions in 61 year old female

Reported by a physician from Japan on 2011-12-23

Patient: 61 year old female

Reactions: C-Reactive Protein Increased, Neoplasm Malignant, Condition Aggravated, Myelodysplastic Syndrome, Pyrexia, Infection

Adverse event resulted in: hospitalization

Suspect drug(s):
Desferal



See index of all Desferal side effect reports >>

Drug label data at the top of this Page last updated: 2012-01-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017